Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Glioma
100%
Glioblastoma
46%
Isocitrate Dehydrogenase 1 (IDH1)
44%
Glioma Risk
41%
Tumor
37%
Genome-wide Association Study
34%
Meningioma
32%
Mayo Clinic
26%
IDH-mutant Glioma
20%
Autoimmunity
19%
Overall Survival
19%
Genetic Risk
19%
Radiotherapy
18%
Odds Ratio
17%
Single nucleotide Polymorphism
17%
Seizure
16%
High-grade Glioma
15%
Central Nervous System
15%
Adult Gliomas
14%
Paraneoplastic
14%
Autoimmune
14%
Germline Variants
14%
Glioma Patients
13%
International Case
12%
Meta-analysis
12%
Autoantibodies
12%
1p/19q Codeletion
12%
Gross Total Resection
12%
SNP
12%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
11%
Low-grade Glioma
11%
Familial Glioma
11%
Clinical Management
10%
Stroke Mimics
10%
95% Confidence Interval
10%
Primary Brain Tumor
10%
Radiation Therapy
10%
Multiple Sclerosis
10%
Risk Loci
10%
8q24.21
10%
Astrocytoma
9%
Age at Diagnosis
9%
Hazard Ratio
9%
Gliomagenesis
9%
Oncologic
9%
Paraneoplastic Syndrome
9%
Cyclophosphamide
8%
TERT Promoter mutation
8%
Progression-free Survival
8%
Germline
8%
Medicine and Dentistry
Ganglioglioma
92%
Glioblastoma
44%
Autoimmunity
25%
Tumor
24%
Magnetic Resonance Imaging
21%
Neoplasm
21%
Radiation Therapy
19%
Genetics
19%
Case-Control Study
19%
Malignant Neoplasm
18%
Overall Survival
17%
Chemotherapy
15%
Diseases
12%
Central Nervous System
12%
Genome Wide Association Study
12%
Isocitrate Dehydrogenase
11%
Neurologic Disease
11%
Intracranial Tumor
11%
Autoantibodies
11%
Meningioma
10%
Rheumatoid Arthritis
10%
Inflammatory Arthritis
10%
Oligoastrocytoma
10%
Neuropathy
10%
Meta-Analysis
9%
Odds Ratio
9%
Demyelination
8%
Cyclophosphamide
8%
Multiple Sclerosis
8%
Socioeconomic Status
8%
Epileptic Seizure
8%
Cancer Registry
8%
Neuro-Oncology
7%
Cancer
7%
Apoplexy
7%
Paraneoplastic Syndrome
7%
Chemotherapy-Induced Peripheral Neuropathy
7%
Histology
7%
Hazard Ratio
6%
Progression Free Survival
6%
Immunotherapy
6%
Allele
6%
Single Nucleotide Polymorphism
6%
Adenocarcinoma
6%
Promoter Region
6%
Thymus Cancer
5%
Differential Diagnosis
5%
Treatment Modality
5%
Hodgkin's Lymphoma
5%
Etiology
5%